CS10 (Cagrilintide 5 mg + Semaglutide 5 mg) – Dual GLP-1 / Amylin agonist

CS10 Blend (Cagrilintide + Semaglutide)?

CS10 is a ready-made combination of two receptor agonists: the amylin analog Cagrilintide (5 mg) and the GLP-1 receptor agonist Semaglutide (5 mg) in a single vial. In the clinical literature the cagrilintide + semaglutide combination is studied in the context of obesity and metabolic disorders.

CS10 combines two separate receptor systems. Semaglutide acts on the incretin axis (the GLP-1 receptor), and cagrilintide — on the amylin pathway. Because these are different receptor mechanisms, the combination is studied as simultaneous signaling at both receptor systems. This distinguishes CS10 from single agonists, such as Tirzepatide or Retatrutide, which combine incretin axes within a single molecule.

CS10 (cagrilintide + semaglutide) is studied in the context of obesity (the REDEFINE 1 program) and type 2 diabetes (REDEFINE 2). According to publicly available data it remains an experimental molecule and holds no registration. In the EU it is not authorized for clinical use. See also the other peptides for weight loss (GLP-1) in our category.

In the version offered by Peptology, CS10 is supplied as a lyophilized research peptide with purity above 99% (HPLC/MS), confirmed by independent laboratory analysis (CoA for every batch), in a fixed composition of Cagrilintide 5 mg + Semaglutide 5 mg. The product is intended exclusively for scientific research and in vitro applications and is not a medicinal product.

Composition: Cagrilintide 5 mg + Semaglutide 5 mg

CS10 is a fixed combination of two peptides in a single lyophilized vial — 10 mg of peptide substance in total. Each component acts on a different pathway, and together they form a dual amylin + GLP-1 mechanism.

The fixed 5 mg + 5 mg composition has purity > 99% and a laboratory certificate for the batch. Both components are reconstituted simultaneously in one vial.

How CS10 works — the dual amylin + GLP-1 pathway

In clinical publications, the cagrilintide + semaglutide combination is described as simultaneous activation of two independent receptor systems — the amylin and calcitonin receptors and the GLP-1 receptor. Because amylin and GLP-1 stimulate different receptors, the two pathways complement each other.

Why combining two pathways matters

Single molecules — even multi-receptor incretins like Tirzepatide — act within the incretin system. CS10 adds a completely different pathway (amylin), which studies examine as simultaneous signaling at two independent receptor systems. This makes CS10 a model research tool for studying combined amylin + GLP-1 strategies.

This concept is being studied in an extensive phase 3 program (REDEFINE 1 in obesity, REDEFINE 2 in type 2 diabetes). The results presented come from controlled clinical trials and do not constitute a claim about the effect of the research-grade product.

Pharmacokinetics and pharmacodynamics of CS10

Both components of CS10 are acylated peptides with a long half-life thanks to albumin binding — which explains the convenient, weekly dosing schedule used in clinical protocols for the combination.

• Half-life (semaglutide): about 7 days (~168 h)
• Half-life (cagrilintide): about 7–8 days (~180 h)
• Dosing schedule: once a week subcutaneously (SC), with dose titration over time
• Long-action mechanism: binding of both components to albumin via fatty-acid residues
• Profile: matched half-lives allow the combination to be administered in a single, weekly schedule
• Doses studied in phase 3 (combination): cagrilintide 2.4 mg + semaglutide 2.4 mg SC weekly, with titration

CS10 vs Semaglutide vs Cagrilintide

The table below compares the CS10 combination with its two single components. This is the most telling comparison, because it comes from a single study (REDEFINE 1), in which all three arms were assessed in parallel — and it shows the additive effect of two pathways. The data are scientific and informational in nature.

Sources: the REDEFINE 1 program (obesity, n≈3417) and REDEFINE 2 (type 2 diabetes, n≈1206) for the cagrilintide + semaglutide combination (NEJM 2025). All arms of REDEFINE 1 were assessed in a single study, which makes this comparison consistent; it does not, however, constitute a claim about the effect of the research-grade product.

Clinical trials of CS10 (cagrilintide + semaglutide)

The clinical program of the cagrilintide + semaglutide combination is being developed in two main phase 3 studies — REDEFINE 1 (obesity) and REDEFINE 2 (type 2 diabetes). These results come from controlled clinical trials.

Scientific basis — the single components

Each component of CS10 has its own clinical program: semaglutide in the STEP (obesity) and SUSTAIN (type 2 diabetes) studies, and cagrilintide in a dose-finding phase 2 study in obesity. The combination was created to combine two independent receptor systems in a single, weekly schedule.

REDEFINE 1 — obesity (NEJM, 2025)

In the phase 3 study REDEFINE 1 (about 3417 adults with obesity without diabetes, 68 weeks), the cagrilintide + semaglutide combination produced a mean weight reduction of 20.4%, versus 11.5% for cagrilintide alone, 14.9% for semaglutide alone and 3.0% for placebo. A weight reduction of ≥ 20% was achieved by about 60% of participants, and ≥ 30% — by about 23%. These results come from a controlled clinical trial and do not constitute a recommendation for individual use.

REDEFINE 2 — type 2 diabetes (NEJM, 2025)

In the REDEFINE 2 study (about 1206 adults with type 2 diabetes and overweight/obesity, 68 weeks), the combination produced a weight reduction of −15.7% versus −3.1% in the placebo group, with a significant improvement in glycemic control. A weight reduction of ≥ 15% was achieved by 51.6% of participants. These results come from a controlled clinical trial.

Note: The information on clinical trials concerns the cagrilintide + semaglutide combination and is presented for scientific and informational purposes. It does not constitute medical advice, a recommendation for use or a claim about the effect of the research-grade product offered by Peptology.

Documented clinical results of CS10 (cagrilintide + semaglutide)

• Ready-made amylin + GLP-1 combination — two independent receptor systems in a single vial
• Mean weight reduction of 20.4% over 68 weeks in phase 3 REDEFINE 1 — more than either component alone
• About 60% of participants with a ≥ 20% reduction and about 23% with a ≥ 30% weight reduction (REDEFINE 1)
• Weight reduction of −15.7% in patients with type 2 diabetes in REDEFINE 2, with improved glycemic control
• Additive effect confirmed by the combination's higher results than cagrilintide alone (11.5%) or semaglutide alone (14.9%)
• Matched half-lives (~7 days) of both components — a single, weekly schedule

All results given concern published clinical trials of the cagrilintide + semaglutide combination and should not be interpreted as a promise of effect, an instruction for use or a claim about the effect of the research-grade product offered by Peptology.

Research dosing protocols

In the REDEFINE clinical program, the combination was used in a weekly subcutaneous schedule with gradual dose titration — which aims to improve gastrointestinal tolerability:

• Components: cagrilintide + semaglutide administered simultaneously once a week SC
• Phase 3 (REDEFINE): target dose cagrilintide 2.4 mg + semaglutide 2.4 mg SC weekly
• Titration schedule: a slow dose increase over several weeks to improve tolerability
• Reconstitution: both components in one vial — they are reconstituted together with a single solvent

Like the single molecules — Semaglutide and Cagrilintide — CS10 in studies requires slow titration to improve tolerability. These schedules are part of controlled clinical trials and do not constitute a recommendation for self-administration.

Storage and reconstitution

CS10 is supplied as a lyophilized (freeze-dried) powder in a vial containing both components. In lyophilized form the peptides are stable at room temperature, protected from light and moisture — refrigeration before reconstitution is not mandatory. After reconstitution, stability depends on the solvent used, with Peptide Matrix Water™ significantly extending the peptides' lifespan.

• Before reconstitution: room temperature, in the original packaging, protected from light and moisture. A refrigerator is not mandatory.
• After reconstitution with Peptide Matrix Water™: stability in the refrigerator +2 °C to +8 °C for up to 60 days under appropriate laboratory conditions — the stabilizing formula extends the peptides' lifespan relative to standard solvents.
• After reconstitution with bacteriostatic or sterile water: stability in the refrigerator +2 °C to +8 °C for up to 28 days under appropriate conditions. Do not refreeze the reconstituted solution.
• Reconstitution: both components are reconstituted simultaneously in one vial; Peptide Matrix Water™, bacteriostatic water or sterile water for injection is usually used.
• Volume: maximum 3 mL of solvent (capacity of a standard vial). For a precise calculation of volume and units, use the peptide calculator.
• Homogenization: add the solvent slowly down the vial wall, without vigorous shaking — peptide bonds are sensitive to mechanical stress. Swirl gently, do not shake.

Laboratory tip: With your order, you can add Peptide Matrix Water™ to the cart — a stabilizing solution designed for working with reconstituted research peptides, including GLP-1 / amylin combinations. More in the article Bacteriostatic water vs acetic acid vs matrix water.

Frequently asked questions about CS10

What exactly is CS10?

CS10 is a ready-made combination of an amylin analog (Cagrilintide 5 mg) and a GLP-1 agonist (Semaglutide 5 mg) in a single vial. The results come from controlled clinical trials.

What does one CS10 vial contain?

CS10 has a fixed composition: Cagrilintide 5 mg + Semaglutide 5 mg (10 mg of peptide substance in total) in a single lyophilized vial. Both components are reconstituted simultaneously.

How is CS10 stored and reconstituted?

The lyophilized vial is stored at room temperature, protected from light and moisture — without the need for cooling before reconstitution. After reconstitution, stability depends on the solvent: with Peptide Matrix Water™ — up to 60 days in the refrigerator +2 °C to +8 °C; with bacteriostatic or sterile water — up to 28 days. Avoid refreezing.

Where to buy CS10 for research?

Peptology offers CS10 (Cagrilintide 5 mg + Semaglutide 5 mg) as a research peptide with confirmed purity above 99% (HPLC/MS) and independent laboratory analysis for every batch. Fast shipping, discreet packaging and certificates of purity with the product. For scientific background, also see the article Peptides — what they are, how they work, main categories and safety profile.

Related peptides in the Peptology catalog

Researchers working with CS10 often also consider its single components and other molecules from the GLP-1 agonist / incretin class. Each of the products below has a certificate of purity above 99%:

See the full catalog: Peptides for weight loss (GLP-1) · Solutions for peptides · Blog on peptide research

References

1. Garvey WT et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025;393:635–647.
2. Davies MJ et al. Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. 2025;393:648–659.

Laboratory reconstitution

Laboratory protocol — reconstitution, research protocols, storage

Standardized protocol applicable to all research peptides in the Peptology catalogue. To calculate the solution concentration (mg/mL) for each vial, use the peptide reconstitution calculator.

60-second protocol

Quick reference

What you need

Five rules for reconstitution

Calculating concentration

Storage

Four mistakes to avoid

Shipping information

🚚 Shipping information

• Products in our warehouse – orders placed by 15:00 on working days are dispatched the same day, later orders on the next working day.

• Delivery with GLS to your address in 3–5 working days.

• Shipping costs €5 and is free from €50.

Frequently Asked Questions (FAQ)

In what form is CS10 supplied and how should it be stored?

It is supplied as a lyophilized (freeze-dried) powder in a sealed vial. Store the unopened vial dry and protected from light, ideally at 2–8 °C. After laboratory reconstitution, keep the solution at 2–8 °C and use it within the period stated in the “Laboratory reconstitution” tab (up to 60 days with Peptide Matrix Water).

What purity does CS10 have and how is it tested?

Every batch has a purity of 99% or higher, confirmed by HPLC and mass spectrometry (MS) and documented in a certificate of analysis (CoA). The report for the current batch is shown in the “Laboratory Analysis” tab.

Is a prescription required?

No. The product is for laboratory and research use only.

Where can I buy CS10 in Europe and what does it cost?

You can buy CS10 in Europe online from Peptology, from 75,00 €. Delivery with GLS in 3–5 working days. Shipping is free from 50,00 €. Payment by card. Purity 99%+, with an HPLC report for every batch.

Laboratory Analysis

CS10 (Cagrilintide 5 mg + Semaglutide 5 mg) - Batch - 0226 - Purity